Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2011 2
2012 3
2013 1
2014 3
2015 6
2016 4
2017 4
2018 4
2019 4
2020 4
2021 7
2022 11
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
TERT promoter mutations in familial and sporadic melanoma.
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. Horn S, et al. Science. 2013 Feb 22;339(6122):959-61. doi: 10.1126/science.1230062. Epub 2013 Jan 24. Science. 2013. PMID: 23348503
PTK7 is a positive allosteric modulator of GPR133 signaling in glioblastoma.
Frenster JD, Erdjument-Bromage H, Stephan G, Ravn-Boess N, Wang S, Liu W, Bready D, Wilcox J, Kieslich B, Jankovic M, Wilde C, Horn S, Sträter N, Liebscher I, Schöneberg T, Fenyo D, Neubert TA, Placantonakis DG. Frenster JD, et al. Among authors: horn s. Cell Rep. 2023 Jul 25;42(7):112679. doi: 10.1016/j.celrep.2023.112679. Epub 2023 Jun 23. Cell Rep. 2023. PMID: 37354459 Free PMC article.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: horn s. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, Kähler K, Grimmelmann I, Gutzmer R, Utikal J, Terheyden P, Herbst R, Haferkamp S, Pfoehler C, Forschner A, Leiter U, Ziller F, Meiss F, Ulrich J, Kreuter A, Gebhardt C, Welzel J, Schilling B, Kaatz M, Scharfetter-Kochanek K, Dippel E, Nashan D, Sachse M, Weishaupt C, Löffler H, Gambichler T, Loquai C, Heinzerling L, Grabbe S, Debus D, Schley G, Hassel JC, Weyandt G, Trommer M, Lodde G, Placke JM, Zimmer L, Livingstone E, Becker JC, Horn S, Schadendorf D, Ugurel S. Franklin C, et al. Among authors: horn s. J Immunother Cancer. 2023 Apr;11(4):e005828. doi: 10.1136/jitc-2022-005828. J Immunother Cancer. 2023. PMID: 37028819 Free PMC article.
Regimes of Coriolis-Centrifugal Convection.
Horn S, Aurnou JM. Horn S, et al. Phys Rev Lett. 2018 May 18;120(20):204502. doi: 10.1103/PhysRevLett.120.204502. Phys Rev Lett. 2018. PMID: 29864299
Persister state-directed transitioning and vulnerability in melanoma.
Chauvistré H, Shannan B, Daignault-Mill SM, Ju RJ, Picard D, Egetemaier S, Váraljai R, Gibhardt CS, Sechi A, Kaschani F, Keminer O, Stehbens SJ, Liu Q, Yin X, Jeyakumar K, Vogel FCE, Krepler C, Rebecca VW, Kubat L, Lueong SS, Forster J, Horn S, Remke M, Ehrmann M, Paschen A, Becker JC, Helfrich I, Rauh D, Kaiser M, Gul S, Herlyn M, Bogeski I, Rodríguez-López JN, Haass NK, Schadendorf D, Roesch A. Chauvistré H, et al. Among authors: horn s. Nat Commun. 2022 Jun 1;13(1):3055. doi: 10.1038/s41467-022-30641-9. Nat Commun. 2022. PMID: 35650266 Free PMC article.
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: horn s. Nat Cancer. 2023 Sep;4(9):1395. doi: 10.1038/s43018-023-00632-w. Nat Cancer. 2023. PMID: 37580519 Free PMC article. No abstract available.
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
Stupia S, Heeke C, Brüggemann A, Zaremba A, Thier B, Kretz J, Sucker A, Philip M, Zelinskyy G, Ferrone S, Roesch A, Horn S, Hadaschik E, Schadendorf D, Trilling M, Dittmer U, Griewank K, Zhao F, Paschen A. Stupia S, et al. Among authors: horn s. Clin Cancer Res. 2023 Aug 1;29(15):2894-2907. doi: 10.1158/1078-0432.CCR-23-0099. Clin Cancer Res. 2023. PMID: 37199727
62 results